©2024 Stanford Medicine
G551D Observational Study- Expanded to Additional Genotypes and Extended for Long Therm Follow up (GOAL-e2)
Not Recruiting
Trial ID: NCT01521338
Purpose
The goal of this research study is to collect blood and urine samples from people who have
either the R117H type of CF or the non-G551D gating type of CF to be kept for future
research.We will also use some of the collected blood to measure the number of neutrophils.
Official Title
G551D Observational Study (GOAL)-Expanded to Additional Genotypes and Extended for Long Term Follow up (GOAL-e2)
Stanford Investigator(s)
Eligibility
Inclusion Criteria for Core Study:
1. Male or female ≥ 6 years of age at Visit 1. :
2. Must have a clinical diagnosis of cystic fibrosis and the following CFTR mutations:
1. For Cohort 1 (Closed to enrollment June 30, 2012):
G551D on at least 1 allele Any known or unknown mutations allowed on second
allele.
2. For Cohort 2:
R117H on at least 1 allele Any known or unknown mutation on the second allele
except G551D
3. For Cohort 3:
A Non-G551D gating mutation on one allele: (G178R, S549N, S549R, G551S,G970R, G1244E,
S1251N, S1255P, G1349D) Any known or unknown mutation on the second allele except
G551D OR R117H
3. Enrolled in the Cystic Fibrosis Foundation Patient Registry (with the exception of
Canadian sites). (Patients may enroll in the Registry at Visit 1 if not previously
enrolled.)
4. Clinically stable with no significant changes in health status within the 14 days
prior to Visit 1.
5. Written informed consent (and assent when applicable) obtained from subject or
subject's legal representative.
Exclusion Criteria for Core Study
1. Participation in the VX-770-105, VX-770-106, VX-770-108, VX-770-110, VX-770-111,
VX-770-112, or VX-770-113 study, VX-770 Extended Access Program or use of ivacaftor
within 6 months prior to Visit 1.
2. Any upper or lower respiratory symptoms requiring treatment with oral, inhaled or IV
antibiotics within the 2 weeks prior to Visit 1.
3. History of solid organ transplantation.
4. Presence of a condition or abnormality that in the opinion of the investigator would
compromise the safety of the patient or the quality of the data.
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Angela Leung
6507235193